Clinical trials for severe sepsis. Past failures, and future hopes.
about
Drotrecogin alfa (activated): the first FDA-approved treatment for severe sepsisClinical review: Hypertonic saline resuscitation in sepsis.Neutrophils from critically ill septic patients mediate profound loss of endothelial barrier integrityThe evolution of an inflammatory response.Differential tumor necrosis factor alpha expression and release from peritoneal mouse macrophages in vitro in response to proliferating gram-positive versus gram-negative bacteria.Plasminogen activators in inflammation and sepsis.Recombinant human activated protein C for use in severe sepsis.Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.Accuracy of early rapid ultrasound in shock (RUSH) examination performed by emergency physician for diagnosis of shock etiology in critically ill patientsSevere sepsis and septic shock: defining the clinical problem.Regulation of inflammatory responses by activated protein C: the molecular mechanism(s) and therapeutic implications.How to approach genome wars in sepsis?Pathobiology of sepsis: are we still asking the same questions?Cathelicidins and functional analogues as antisepsis molecules.Epithelial cell apoptosis and neutrophil recruitment in acute lung injury-a unifying hypothesis? What we have learned from small interfering RNAs.Meta-analysis of protocolized goal-directed hemodynamic optimization for the management of severe sepsis and septic shock in the Emergency Department.The difficulties of clinical trials evaluating therapeutic agents in patients with severe sepsis.Immunization with an anti-idiotypic antibody against the broadly lipopolysaccharide-reactive antibody WN1 222-5 induces Escherichia coli R3-core-type specific antibodies in rabbits.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Differential effects of glucocorticoids in the establishment and maintenance of endotoxin tolerance.Role of clinical evaluation committees in sepsis trials: from 'valid cohort' assessment to subgroup analysis.Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice.The effects of hemodilution on acute inflammatory responses in a bleomycin-induced lung injury model.Interleukin-1beta induces in vivo tolerance to lipopolysaccharide in mice.Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).Transcriptional response signature of human lymphoid cells to staphylococcal enterotoxin B.Drotrecogin Alfa (Activated): The First Fda-Approved Treatment for Severe Sepsis
P2860
Q24536981-7601AE12-D246-4324-A859-460C2E7D0E88Q24797110-FC40E673-3FE6-424C-8EB4-EF50D0CE8C83Q33753767-5C1E7913-1DE2-4565-96EF-A12B76D9454EQ33762821-99D37C8B-F4D3-4F44-B8BF-EEC497D675B4Q34007548-40019215-1E82-4084-BAF6-955807807BD2Q34777701-4F871C1F-D9AC-45BF-A00F-BFE2F7F2DA7AQ34796994-246BBFC1-77AA-4C2F-94C3-9ECACDDF73A8Q35059326-A132CCD8-4973-483E-8F71-7443ED982382Q35103760-D26C433C-A6B2-4FCB-933C-92F77F06763EQ35585020-CDCA586B-41B7-4F24-AAA5-8838E23C377CQ35733494-AB9B099F-780C-408B-8A14-5EBE93E2BBAAQ36073092-773791D1-ABFF-458E-8F54-7822CBE34459Q36371860-0AA268F0-21CA-47C0-BECA-97CFDDD7A4ECQ36897327-2FE1C0D3-E23B-48D3-9705-B8F3E0C4A322Q37119723-D74B61A9-68FC-4906-BE69-5880CE9B543DQ37635401-69F0E192-AE99-4336-B20A-097C562D57CCQ37953865-2FEA3A50-B51F-41EE-9D99-AA02B286582FQ38332611-EB3952D1-3096-4779-A85B-C9E88BD0CD61Q38954348-E128D9A1-DF3D-48A8-AFD7-46D7407CD1BCQ39929445-861E8A8A-4AD0-44C5-A76E-6CEADE717B84Q39979975-BA3FCEA8-737D-43EA-B5FF-FCAA877E1927Q43221756-A16E5DB4-C834-4507-A506-D89383687E8FQ43227519-FA579C45-A684-490E-88F9-C1D3CB8F53F5Q44012712-C6B15A6A-F742-43E5-A412-8BACC351F896Q47799201-30762893-5296-4434-B4A5-E00D3D666517Q47859097-60580DE1-06DA-4584-A6FA-02375C2CD5A5Q56502502-8958D18B-BD7B-4A1E-BE3E-F464D56CF319
P2860
Clinical trials for severe sepsis. Past failures, and future hopes.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Clinical trials for severe sepsis. Past failures, and future hopes.
@ast
Clinical trials for severe sepsis. Past failures, and future hopes.
@en
type
label
Clinical trials for severe sepsis. Past failures, and future hopes.
@ast
Clinical trials for severe sepsis. Past failures, and future hopes.
@en
prefLabel
Clinical trials for severe sepsis. Past failures, and future hopes.
@ast
Clinical trials for severe sepsis. Past failures, and future hopes.
@en
P1476
Clinical trials for severe sepsis. Past failures, and future hopes.
@en
P2093
P304
285-97, vii
P356
10.1016/S0891-5520(05)70075-1
P577
1999-06-01T00:00:00Z